-
11دورية أكاديمية
المؤلفون: Toshiki Terao, Takafumi Tsushima, Daisuke Miura, Kentaro Narita, Masami Takeuchi, Kosei Matsue
المصدر: eJHaem, Vol 1, Iss 1, Pp 103-112 (2020)
مصطلحات موضوعية: International Myeloma Working Group, International Staging System, multiple myeloma, physical frailty, social frailty, Diseases of the blood and blood-forming organs, RC633-647.5
وصف الملف: electronic resource
العلاقة: https://doaj.org/toc/2688-6146Test
-
12دورية أكاديمية
المؤلفون: Harrison, Simon J., Perrot, Aurore, Alegre, Adrian, Simpson, David, Wang, Ming Chung, Spencer, Andrew, Delimpasi, Sosana, Hulin, Cyrille, Sunami, Kazutaka, Facon, Thierry, Vlummens, Philip, Yong, Kwee, Campana, Frank, Inchauspe, Marlene, Mace, Sandrine, Risse, Marie-Laure, Velde, Helgi, Richardson, Paul
المصدر: BRITISH JOURNAL OF HAEMATOLOGY ; ISSN: 0007-1048 ; ISSN: 1365-2141
مصطلحات موضوعية: Medicine and Health Sciences, INTERNATIONAL STAGING SYSTEM, LOW-DOSE DEXAMETHASONE, MOLECULAR, CLASSIFICATION, INTERGROUPE FRANCOPHONE, LENALIDOMIDE, ABNORMALITIES, POMALIDOMIDE, EXPRESSION, BORTEZOMIB, SAR650984, cytogenetics, gain (1q21), high‐, risk, isatuximab, relapsed, refractory multiple myeloma
وصف الملف: application/pdf
العلاقة: https://biblio.ugent.be/publication/8710949Test; http://hdl.handle.net/1854/LU-8710949Test; http://dx.doi.org/10.1111/bjh.17499Test; https://biblio.ugent.be/publication/8710949/file/8710950Test
الإتاحة: https://doi.org/10.1111/bjh.17499Test
https://biblio.ugent.be/publication/8710949Test
http://hdl.handle.net/1854/LU-8710949Test
https://biblio.ugent.be/publication/8710949/file/8710950Test -
13دورية أكاديمية
المؤلفون: Truska A. Amin, Zeki A. Mohamed
المصدر: Zanco Journal of Pure and Applied Sciences, Vol 32, Iss 6 (2020)
مصطلحات موضوعية: international staging system (iss), kurdistan, multiple myeloma, time lapse, Technology, Science
وصف الملف: electronic resource
العلاقة: https://zancojournals.su.edu.krd/index.php/JPAS/article/view/3694Test; https://doaj.org/toc/2218-0230Test; https://doaj.org/toc/2412-3986Test
-
14دورية أكاديمية
المؤلفون: Keiichi Akizuki, Hitoshi Matsuoka, Takanori Toyama, Ayako Kamiunten, Masaaki Sekine, Kotaro Shide, Takuro Kameda, Noriaki Kawano, Kouichi Maeda, Masanori Takeuchi, Hiroshi Kawano, Seiichi Sato, Junzo Ishizaki, Yuki Tahira, Haruko Shimoda, Tomonori Hidaka, Kiyoshi Yamashita, Yoko Kubuki, Kazuya Shimoda
المصدر: Journal of Clinical Medicine; Volume 10; Issue 1; Pages: 105
مصطلحات موضوعية: real-world outcomes, prognostic factors, multiple myeloma, international staging system
وصف الملف: application/pdf
العلاقة: Hematology; https://dx.doi.org/10.3390/jcm10010105Test
-
15دورية أكاديمية
المؤلفون: Tuğçe Nur Yiğenoğlu, Semih Başcı, Mehmet Bakırtaş, Bahar Uncu Ulu, Derya Şahin, Tahir Darçın, Jale Yıldız, Nuran Ahu Baysal, Dicle İskender, Merih Kızıl Çakar, Mehmet Sinan Dal, Fevzi Altuntaş
المصدر: Dicle Medical Journal, Vol 47, Iss 2, Pp 237-242 (2020)
مصطلحات موضوعية: multipl myeloma, renal failure, international staging system, Medicine, Medicine (General), R5-920
العلاقة: http://diclemedj.org/upload/sayi/77/Dicle%20Med%20J-04041.pdfTest; https://doaj.org/toc/1300-2945Test; https://doaj.org/toc/1308-9889Test; https://doaj.org/article/5a2cd2665ebc4c46b374bd8808cddb7fTest
الإتاحة: https://doi.org/10.5798/dicletip.748566Test
https://doaj.org/article/5a2cd2665ebc4c46b374bd8808cddb7fTest -
16دورية أكاديمية
المؤلفون: Pouzoullic, Marie, Sánchez-Rodríguez, Dolores, Bataille, Regis, Annweiler, Cédric, Schott, Anne-Marie
المساهمون: Faculté de Médecine, Université d'Auvergne - Clermont-Ferrand I (UdA), Laboratoire de Psychologie des Pays de la Loire (LPPL), Université d'Angers (UA)-Université de Nantes - UFR Lettres et Langages (UFRLL), Université de Nantes (UN)-Université de Nantes (UN)
المصدر: ISSN: 0953-6205.
مصطلحات موضوعية: Albumin, Beta-2 microglobulin, Multiple myeloma international staging system, Prognosis, Survival, Older adults, [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology
العلاقة: hal-03345452; https://hal-nantes-universite.archives-ouvertes.fr/hal-03345452Test; https://hal-nantes-universite.archives-ouvertes.fr/hal-03345452/documentTest; https://hal-nantes-universite.archives-ouvertes.fr/hal-03345452/file/S0953620519302663.pdfTest; PII: S0953-6205(19)30266-3
الإتاحة: https://doi.org/10.1016/j.ejim.2019.07.031Test
https://hal-nantes-universite.archives-ouvertes.fr/hal-03345452Test
https://hal-nantes-universite.archives-ouvertes.fr/hal-03345452/documentTest
https://hal-nantes-universite.archives-ouvertes.fr/hal-03345452/file/S0953620519302663.pdfTest -
17دورية أكاديمية
المؤلفون: Mohty, M, Cavo, M, Fink, L, Gonzalez-McQuire, S, Leleu, H, Mateos, M-V, Raab, MS, Schoen, P, Yong, K
المصدر: European Journal of Haematology , 103 (2) pp. 107-115. (2019)
مصطلحات موضوعية: Science & Technology, Life Sciences & Biomedicine, Hematology, death, Europe, mortality, multiple myeloma, risk, survival, INTERNATIONAL STAGING SYSTEM, COMORBIDITY, PATTERNS, IMPACT
وصف الملف: text
العلاقة: https://discovery.ucl.ac.uk/id/eprint/10080070/1/Mohty_et_al-2019-European_Journal_of_Haematology.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10080070Test/
-
18دورية أكاديمية
-
19رسالة جامعية
المؤلفون: Pedraza Morales, Julian Eduardo
المساهمون: Villar Centeno, Luis Ángel, Abello Polo, Virginia, Villar Centeno, Luis Ángel 0000048488, Abello Polo, Virginia 0000744212, Villar Centeno, Luis Ángel es&oi=ao, Abello Polo, Virginia es&oi=ao, Pedraza Morales, Julian Eduardo 0000-0001-6744-2469, Abello Polo, Virginia 0000-0001-6507-4041
مصطلحات موضوعية: Medical sciences, Health sciences, Overall Survival (OS), Kaplan-Meier (KM), Discrimination, Calibration, Progression-free survival (PFS), International staging system (ISS), Risk model validation, Multiple myeloma (MM), National registry of hematological oncological diseases in Colombia (RENEHOC), Plasma cell diseases, Medical literature, Epidemiology, Neoplasms, Ciencias médicas, Enfermedades de las células plasmáticas, Literatura médica, Ciencias de la salud, Epidemiología, Neoplasmas, Mieloma múltiple (MM), Supervivencia global (SG), Supervivencia libre de progresión (SLP), Índice de Estadificación Internacional (ISS), Validación, Registro nacional de enfermedades hematológicas oncológicas en Colombia (RENEHOC), Modelos de riesgo, Discriminación, Calibración
جغرافية الموضوع: Colombia, UNAB Campus Bucaramanga
الوقت: 2022-2023
وصف الملف: application/pdf
العلاقة: Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. 2018; Ludwig H, Bolejack V, Crowley J, Bladé J, San Miguel J, Kyle RA, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. Journal of Clinical Oncology. 2010 Mar 20;28(9):1599–605.; Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer [Internet]. 2021 Dec 1 [cited 2023 Jan 17];21(1):1–13. Available from: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08280-yTest; Cuenta de alto costo. Cuenta de alto costo. 2022 [cited 2022 Sep 14]. SITUACIÓN DEL CÁNCER Transformando la información en acciones para una mejor salud EN LA POBLACIÓN ADULTA ATENDIDA EN EL SGSSS DE COLOMBIA 2021. Available from: https://cuentadealtocosto.org/site/wp-content/uploads/2022/08/01_agosto_libro_cancer_2021_final.pdfTest; Divi-Sion Of Hematology KS. From the Division of Hematology/Oncology. Mayo Clin Proc n April [Internet]. 2013 [cited 2022 Dec 25];88(4):360–76. Available from: http://dxTest.; D’agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology. 2022 May 1;364.; Avet-Loiseau H, Durie BGM, Cavo M, Attal M, Gutierrez N, Haessler J, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 2013 27:3 [Internet]. 2012 Oct 3 [cited 2023 Jan 1];27(3):711–7. Available from: https://www-nature-com.aure.unab.edu.co/articles/leu2012282Test; Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey A, To LB, et al. Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia 2009 23:8 [Internet]. 2009 Mar 26 [cited 2023 Jan 20];23(8):1528–34. Available from: https://www-nature-com.aure.unab.edu.co/articles/leu200961Test; Overview %7C Myeloma: diagnosis and management %7C Guidance %7C NICE [Internet]. [cited 2023 Jan 23]. Available from: https://www.nice.org.uk/guidance/ng35Test; Sive J, Cuthill K, Hunter H, Kazmi M, Pratt G, Smith D. Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. Br J Haematol. 2021 Apr 1;193(2):245–68.; Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar M V., Kumar S, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. Journal of Clinical Oncology. 2019 Apr 1;37(14):1228–63.; Colombiana de Hematología Oncología -ACHO A. Guía de Práctica Clínica para el tratamiento del mieloma múltiple.; Pessoa de Magalhães Filho RJ, Crusoe E, Riva E, Bujan W, Conte G, Navarro Cabrera JR, et al. Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries. Clin Lymphoma Myeloma Leuk. 2019 Jan 1;19(1):e43–50.; Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. Journal of Clinical Oncology. 2015 Aug 3;33(26):2863–9.; Greipp PR, Miguel JS, Dune BGM, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. Journal of Clinical Oncology. 2005 Sep 21;23(15):3412–20.; Hungria VTM, Maiolino A, Martinez G, Colleoni G, Oliveira L, Coelho EOM, et al. Validation of International Staging System (ISS) for Multiple Myeloma: A Retrospective Analysis of 487 Patients at 8 Brazilian Centers. Blood. 2005 Nov 16;106(11):5069.; D’Agostino M, Waage A, Lahuerta JJ, Bertsch U, Zamagni E, Bullinger L, et al. Validation and Improvement Opportunities of the Revised International Staging System for Multiple Myeloma: An Analysis on Mature Data from European Clinical Trials within the Harmony Big Data Platform. Blood. 2019 Nov 13;134(Supplement_1):1773.; Kent P, Cancelliere C, Boyle E, Cassidy JD, Kongsted A. A conceptual framework for prognostic research. [cited 2023 Feb 21]; Available from: https://doi.org/10.1186/s12874-020-01050-7Test; RENEHOC - ACHO [Internet]. [cited 2023 Jan 23]. Available from: https://acho.com.co/renehocTest/; Abello V, Mantilla WA, Idrobo H, Sossa CL, Salazar LA, Pena A, et al. Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study. Clin Lymphoma Myeloma Leuk. 2022 Jun 1;22(6):e405–13.; Huang J, Chan SC, S Wong MC, Huang J, Chai Chan S, Lok V, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Articles Lancet Haematol [Internet]. 2022 [cited 2023 Jan 11];9:670–7. Available from: www.thelancet.com/haematology; Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 2009 23:10 [Internet]. 2009 Jul 9 [cited 2023 Jan 11];23(10):1691–7. Available from: https://www-nature-com.aure.unab.edu.co/articles/leu2009134Test; Abello V, Mantilla WA, Idrobo H, Sossa CL, Salazar LA, Pena A, et al. Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study. Clin Lymphoma Myeloma Leuk [Internet]. 2022 Jun 1 [cited 2023 Jan 22];22(6):e405–13. Available from: http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152265021024782/fulltextTest; Combariza JF, Ordúz R, Agudelo C, Hernandez S, Madera AM, León G, et al. Incidence and Prognostic Significance of High-Risk Cytogenetically Abnormalities in Multiple Myeloma Patients in Colombia. Clin Lymphoma Myeloma Leuk. 2022 Aug 1;22(8):601–7.; Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK [Internet]. 2009 [cited 2023 Jan 15];23(12):2210. Available from: /pmc/articles/PMC2964268/; Ribatti D. A historical perspective on milestones in multiple myeloma research. Eur J Haematol [Internet]. 2018 Mar 1 [cited 2023 Jan 17];100(3):221–8. Available from: https://pubmed.ncbi.nlm.nih.gov/29194778Test/; Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia [Internet]. 2014 [cited 2023 Jan 17];28(5):1122. Available from: /pmc/articles/PMC4000285/; Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: Updated mayo stratification of myeloma and risk-adapted therapy (msmart) consensus guidelines 2013. Mayo Clin Proc [Internet]. 2013 Apr 1 [cited 2023 Jan 15];88(4):360–76. Available from: http://www.mayoclinicproceedings.org/article/S0025619613000773/fulltextTest; Rajan AM, Rajkumar S V. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J [Internet]. 2015 Oct 30 [cited 2023 Jan 17];5(10). Available from: https://pubmed.ncbi.nlm.nih.gov/26517360Test/; Legües ME, Morales P, Valenzuela M, Encina A, Martí MJ, Bascuñán C, et al. Características citogenéticas y detección de anormalidades de alto riesgo en mieloma múltiple. Rev Med Chil [Internet]. 2019 [cited 2023 Jan 17];147(1):61–4. Available from: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000100061&lng=es&nrm=iso&tlng=esTest; Rosiñ ol L, Oriol A, Isabel Teruel A, Herná ndez D, Ló pez-Jimé nez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. 2012 [cited 2023 Jan 15]; Available from: http://ashpublications.org/blood/article-pdf/120/8/1589/1498997/zh803412001589.pdfTest; Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J [Internet]. 2020 [cited 2023 Jan 15];10:53. Available from: https://doi.org/10.1038/s41408-020-0311-8Test; Devarakonda S, Efebera Y, Sharma N. cancers Role of Stem Cell Transplantation in Multiple Myeloma. 2021 [cited 2023 Jan 18]; Available from: https://doi.org/10.3390/cancers13040863Test; Gay F, Oliva S, Magarotto V, Bs M, Ma S, Omedè P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol [Internet]. 2015 [cited 2023 Jan 18];16:1617–46. Available from: www.thelancet.com/oncology; Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med [Internet]. 2017 Apr 6 [cited 2023 Jan 17];376(14):1311–20. Available from: https://pubmed.ncbi.nlm.nih.gov/28379796Test/; Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321. Journal of Clinical Oncology. 2006 Feb 20;24(6):929–36.; Perrot A, Lauwers-Cances V, Cazaubiel T, Facon T, Caillot D, Clement-Filliatre L, et al. Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. Blood [Internet]. 2020 Nov 5 [cited 2023 Jan 18];136(Supplement 1):39–39. Available from: https://ashpublications.org/blood/article/136/SupplementTest 1/39/470028/Early-Versus-Late-Autologous-Stem-Cell-Transplant; Merlini G, Waldenstrom JG, Jayakar SD. A New Improved Clinical Staging System for Multiple Myeloma Based on Analysis of 123 Treated Patients. Blood. 1980 Jun 1;55(6):1011–9.; Jacobson JL, Hussein MA, Barlogie B, Durie BGM, Crowley JJ. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol. 2003 Aug;122(3):441–50.; Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, et al. ARTICLE OPEN A simple additive staging system for newly diagnosed multiple myeloma. [cited 2023 Apr 3]; Available from: https://doi.org/10.1038/s41408-022-00611-xTest; Terebelo HR, Abonour R, Gasparetto CJ, Toomey K, Durie BGM, Hardin JW, et al. Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry. Br J Haematol. 2019 Dec 1;187(5):602–14.; Norman G, Streiner D. Biostatistics - The bare essentials. 4th edition. Mehta Linda, editor. People’s Medical Publishing House-USA; 2014.; Ma Argimon Pallás J, Jiménez Villa J. Métodos de investigación clínica y epidemiológica 5.a EDICIÓN.; Carolina Alba A, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed.; Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods [Internet]. Vol. 13, Medical Research Methodology. 2013. Available from: http://www.biomedcentral.com/1471-2288/13/33Test; Abello V, Idrobo H, Sossa CL, Galvez KM, Saavedra D, Solano MH, et al. The Status of Multiple Myeloma in Colombia: First Report of the Colombian Registry for Hemato-Oncological Diseases (RENEHOC). Asociacion Colombiana De Hematologia y Oncologia (ACHO). Blood [Internet]. 2018 Nov 29 [cited 2023 Jan 22];132(Supplement 1):5597–5597. Available from: https://ashpublications.org/blood/article/132/SupplementTest 1/5597/263281/The-Status-of-Multiple-Myeloma-in-Colombia-First; Redder L, Klausen TW, Vangsted AJ, Gregersen H, Andersen NF, Pedersen RS, et al. Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry. Br J Haematol. 2021 Apr 1;193(1):119–24.; Cook G, Royle KL, Pawlyn C, Hockaday A, Shah V, Kaiser MF, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol [Internet]. 2019 Mar 1 [cited 2023 Sep 5];6(3):e154. Available from: /pmc/articles/PMC6391517/; http://hdl.handle.net/20.500.12749/22620Test; instname:Universidad Autónoma de Bucaramanga - UNAB; reponame:Repositorio Institucional UNAB; repourl:https://repository.unab.edu.coTest
-
20
المؤلفون: Mattia D'Agostino, David A. Cairns, Juan José Lahuerta, Ruth Wester, Uta Bertsch, Anders Waage, Elena Zamagni, María-Victoria Mateos, Daniele Dall'Olio, Niels W.C.J. van de Donk, Graham Jackson, Serena Rocchi, Hans Salwender, Joan Bladé Creixenti, Bronno van der Holt, Gastone Castellani, Francesca Bonello, Andrea Capra, Elias K. Mai, Jan Dürig, Francesca Gay, Sonja Zweegman, Michele Cavo, Martin F. Kaiser, Hartmut Goldschmidt, Jesús María Hernández Rivas, Alessandra Larocca, Gordon Cook, Jesús F. San-Miguel, Mario Boccadoro, Pieter Sonneveld
المساهمون: Hematology, CCA - Imaging and biomarkers, Anatomy and neurosciences, D'agostino M., Cairns D.A., Lahuerta J.J., Wester R., Bertsch U., Waage A., Zamagni E., Mateos M.-V., Dall'olio D., Van De Donk N.W.C.J., Jackson G., Rocchi S., Salwender H., Blade Creixenti J., Van Der Holt B., Castellani G., Bonello F., Capra A., Mai E.K., Durig J., Gay F., Zweegman S., Cavo M., Kaiser M.F., Goldschmidt H., Hernandez Rivas J.M., Larocca A., Cook G., San-Miguel J.F., Boccadoro M., Sonneveld P.
المصدر: D'agostino, M, Cairns, D A, Lahuerta, J J, Wester, R, Bertsch, U, Waage, A, Zamagni, E, Mateos, M-V, Dall'olio, D, van de Donk, N W C J, Jackson, G, Rocchi, S, Salwender, H, Bladé Creixenti, J, van der Holt, B, Castellani, G, Bonello, F, Capra, A, Mai, E K, Dürig, J, Gay, F, Zweegman, S, Cavo, M, Kaiser, M F, Goldschmidt, H, Hernández Rivas, J M, Larocca, A, Cook, G, San-Miguel, J F, Boccadoro, M & Sonneveld, P 2022, ' Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma : A European Myeloma Network (EMN) Report Within the HARMONY Project ', Journal of Clinical Oncology, vol. 364, JCO.21.02614 . https://doi.org/10.1200/JCO.21.02614Test
Journal of Clinical Oncology, 364:JCO.21.02614. American Society of Clinical Oncologyمصطلحات موضوعية: Chromosome Aberrations, Cancer Research, Oncology, SDG 3 - Good Health and Well-being, Risk Factors, Medizin, Humans, Second Revision, International Staging System, R2-ISS, Overall Survival, Multiple Myeloma, EMN, HARMONY Project, Multiple Myeloma, Prognosis, Neoplasm Staging, Retrospective Studies
وصف الملف: STAMPA; application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a025f927facbe530cb8400ace1b71ffTest
https://research.vumc.nl/en/publications/aa820dce-9edf-4a92-8f14-902a637994b6Test